|
" Neuropsychopharmacology and therapeutics / "
Ivor S. Ebenezer
| Document Type
|
:
|
BL
|
| Record Number
|
:
|
661646
|
| Doc. No
|
:
|
dltt
|
| Main Entry
|
:
|
Ebenezer, Ivor S.
|
| Title & Author
|
:
|
Neuropsychopharmacology and therapeutics /\ Ivor S. Ebenezer
|
| Page. NO
|
:
|
1 online resource
|
| ISBN
|
:
|
9781118385845
|
|
|
:
|
: 1118385845
|
|
|
:
|
: 9781118385784
|
|
|
:
|
: 1118385780
|
|
|
:
|
: 9781118385777
|
|
|
:
|
: 1118385772
|
|
|
:
|
9781118385654
|
| Notes
|
:
|
Machine generated contents note: Preface Chapter1. Introduction to Neuropsychopharmacology Chapter 2. Parkinson's Disease Chapter 3. Memory, Dementia and Alzheimer's Disease Chapter 4. Epilepsy Chapter 5. Attention Deficit Hyperactivity Disorder (ADHD) Chapter 6. Affective Disorders 1:Depression Chapter 7. Affective Disorders 2: Bipolar Disorders Chapter 8. Anxiety Disorders Chapter 9. Sleep and Sleep Disorders Chapter 10. Schizophrenia Chapter 11. Drug Abuse and Misuse Index
|
| Bibliographies/Indexes
|
:
|
Includes bibliographical references and index
|
| Contents
|
:
|
Introduction to Neuropsychopharmacology -- Overview -- A Brief Overview of the Anatomy and Function of the Brain -- The Brainstem -- The Metencephalon -- Diencephalon -- The Telencephalon -- The Cerebral Ventricles and Cerebrospinal Fluid -- Important Neurotransmitters -- GABA and GABA Receptors -- Glutamate and Glutamate Receptors -- Central Nervous System Stimulant and Depressant Drugs -- Central Nervous System (CNS) Stimulant Drugs -- Psychomotor Stimulants -- Analeptic Drugs -- Depressant Drugs -- Benzodiazepines -- Oilier Depressant Drugs -- Genetics -- Electroencephalography and Imaging Techniques -- Electroencephalography -- X-Rays -- Computed Tomography -- Positron Emission Tomography -- Magnetic Resonance Imaging -- Functional MRI -- Diagnostic Criteria for Mental Disorders -- Animals Models for CNS Disorders -- Summary -- Parkinson's Disease -- Overview -- Historical Background -- Epidemiology -- Primary Clinical Features -- Secondary Clinical Features -- Parkinson's Disease and the Extrapyramidal System -- Neurotransmission in the Extrapyramidal System and Parkinson's Disease -- Modulation of the Direct and Indirect Pathways -- Causes of Parkinson's Disease -- Genes and Parkinson's Disease -- Environmental Neurotoxins -- Oxidative Stress -- Summary -- Pharmacotherapy for Parkinson's Disease -- L-DOPA (L-Dihydroxyphenylalaninc) -- L-DOPA Treatment -- Adverse Effects of L-DOPA -- Adverse Effects after Long-Term Treatment -- Alternative Formulations of L-DOPA and Other Pharmacological Agents -- Nonmotor Symptoms of Parkinson' Disease and the Development of a New Hypothesis -- Pharmacological and Nonpharmacological Strategies for Treatment of Other Motor and Nonmotor Symptoms of Parkinson's Disease -- Other Nonpharmacological Methods of Treating Parkinson's Disease -- Lesions of the Globus Pallidus or Subthalamic Nucleus -- Neurostimulation -- Brain Grafts -- Possible Future Strategies to Treat Parkinson's Disease -- Stem Cell Therapy -- Gene Therapy -- Early Diagnosis for Treatment of Parkinson's Disease -- Summary and Conclusions -- Memory, Dementia and Alzheimer's Disease -- Overview -- Learning and Memory -- Temporal Stages of Learning, Memory and Recall -- Where are STM and LTM Stored in the Brain? -- Overview of Dementia -- Alzheimer's Disease (AD) -- Clinical Symptoms of Alzheimer's Disease -- Neuropathological Changes -- Molecular Pathology -- Staging of Alzheimer's Disease -- Onset of Alzheimer's Disease -- Neurochemical Changes in Alzheimer's Disease -- Pharmacotherapy of Alzheimer's Disease -- Future Pharmacological Strategies m the Treatment of Alzheimer's Disease -- Cardiovascular Disease -- Conclusions -- Summary -- Epilepsy -- Overview -- Background -- Classification and Types of Epilepsy -- Focal Seizures -- Generalized Seizures -- Epilepsy Syndromes -- Epidemiology -- Underlying Causes of Epilepsy -- Epileptic Mechanisms -- Electrophysiological Mechanisms -- Mechanisms Underpinning Drug Treatment of Epilepsy -- Pharmacotherapy -- Valproate (Valproic Acid and Sodium Valproate) -- Phenytoin -- Carbamazepine -- Ethosuximide -- Gabapentin -- Pregabalin -- Lamotrigine -- Tiagabine -- Topiramate -- Levetiracetam -- Retigabme -- Zonisannde -- Benzodiazepines -- Barbiturates -- Vagal Nerve Stimulation -- Summary -- Attention Deficit Hyperactivity Disorder -- Overview -- Background to ADHD -- Diagnostic Criteria for ADHD -- ADHD and Comorbidity -- Epidemiology -- Aetiology of ADHD -- Genetic Factors -- Environmental Factors -- The Pathophysiology of ADHD -- The Prefrontal Cortex, Executive Function and ADHD -- Frontocoriical-Striatal Networks and ADHD -- The Biochemical Hypothesis of ADHD -- Executive Functional Skills, Neuredevelopment and ADHD -- Summary of the Pathophysiology of ADHD -- Management of ADHD -- Pharmacotherapy -- Nonpharmacological Management of ADHD -- Summary and Conclusions -- Affective Disorders 1: Depression -- Outline -- Emotion, Mood and Affective Disorders -- Background to Depression -- Clinical Features of Major Depressive Disorder -- Subtypes of Depressive Disorders -- Epidemiology -- Causes of Depression -- Genetic Influences -- Biochemical Hypotheses of Depression -- Stress, Learned Helplessness and Depression -- Stress and MDD -- What is Stress? -- Stress and Depression -- Brain Derived Neurotropic Factor, Neurotropic Effects and Depression -- Genetics, Stress and Depression -- Early-Life Stress, Depression and Epigenedcs -- Depression and Inflammation -- Depression and Glutamate -- Depression and Physical Diseases -- Drug Treatment of Depression -- Overview -- Types of Antidepressant Drug -- Possible Future Drugs for MDD -- Nonpharmacological Treatments for Depression -- Electroconvulsive Therapy -- Transcranial Magnetic Stimulation -- Vagus Nerve Stimulation -- Phototherapy (Light Therapy) -- Deep Brain Stimulation -- Cognitive Behavioural Therapy -- Interpersonal Therapy -- Behavioural Therapy -- Mindfulness-Based Cognitive Therapy -- Summary -- Affective Disorders 2: Bipolar Disorder -- Outline -- Background to Bipolar Disorder -- Clinical Features of Bipolar Disorder and Diagnostic Criteria -- Symptoms of Mania -- Symptoms of Hypomania -- Symptoms of Depression -- Categories of Bipolar Disorder -- Rapid Cycling -- Mixed Features -- Cyclothymia -- Suicide -- Course of Illness -- Epidemiology -- Cause of Bipolar Disorder -- Genetic Factors -- Environmental Factors -- Neurobiology of Bipolar Disorder -- Management of Bipolar Disorder -- Pharmacotherapy -- Drugs Used in the Treatment of Bipolar Disorder -- Pregnancy and Bipolar Disorder -- Psychological Treatments -- Psychoeducation -- Family-Focused Treatment -- Cognitive Behavioural Therapy -- Interpersonal and Social Rhythm Therapy -- Lifestyle Changes -- Summary and Conclusions -- Anxiety Disorders -- Overview -- Background -- Anxiety Disorders and Diagnostic Criteria -- Generalized Anxiety Disorder -- Social Anxiety Disorder -- Panic Attack and Panic Disorder -- Agoraphobia -- Others Types of Anxiety Disorders -- Neurobiology of Anxiety Disorders -- Fear and the Amygdala -- Anatomy and Circuitry of the Amygdala -- Physiological Responses to Fear-Eliciting Stimuli -- Conditioned Fear Response -- Conditioned Fear Extinction -- Worry -- Are there Other Anxiety Circuits? -- Neurotransmitters and Anxiety Disorders -- Management of Anxiety Disorders -- Pharmacotherapy -- Psychosocial Therapies -- Summary and Outcomes -- Sleep and Sleep Disorders -- Overview -- Introduction -- Physiology of Sleep -- Stages of Sleep -- The Ascending Reticular Activating System -- Slow Wave Sleep Mechanisms -- Rapid Eye Movement Sleep Mechanisms -- Sleep Disorders -- Insomnia -- Hypersomnia or Hypersomnolence -- Summary and Conclusions -- Schizophrenia -- Overview -- Background -- Clinical Features of Schizophrenia -- Phases of Schizophrenia -- Diagnostic Criteria for Schizophrenia -- Violence, Self-Harm and Suicide -- General Physical Health and Mortality -- Epidemiology -- Pathology -- Aetiology -- Genetics of Schizophrenia -- Environmental Risk Factors -- Developmental Hypothesis of Schizophrenia -- Biochemical Hypotheses -- Dopamine and the Dopamine Hypothesis of Schizophrenia -- The Mesolimbic System and Schizophrenia -- The Mesocortical System and Schizophrenia -- Glulamate, GABA and Dopamine: A Revised Hypothesis of Schizophrenia -- Management of Schizophrenia -- Pharmacotherapy -- Nonpharmacologieal Management of Schizophrenia -- Summary and Conclusions -- Drug Abuse and Addiction -- Outline -- Background -- Neurobiology of Substance Abuse and Addiction -- The Mesolimbic Reward Systems and Addictive Drugs -- Extensions of the Hypothesis -- Transition from Hedonic Actions to Habits to Compulsions -- Summary -- Risk Factors -- Environmental Factors -- Genetic Factors -- Management of Addiction -- Alcohol -- Heroin -- Summary
|
| Abstract
|
:
|
"Neuropsychopharmacology is a relatively new subject area in the neurosciences. It is a field of study that describes the effects of drugs from the molecular to the behavioural level and requires integration and synthesis of knowledge from various disciplines including neuroanatomy, physiology, molecular biology, pharmacology and the behavioural sciences. The principal aims of this book are to provide students with a clear understanding of CNS disorders, and an appreciation of how basic and clinical research findings can be translated into therapeutics. After an introduction to the subject area, the remaining chapters are focused on reviewing the main psychiatric and neurological disorders that are covered in most courses. They are discussed in terms of their clinical symptoms, epidemiology, pathology, aetiology, underlying neurobiological and neurochemical mechanisms, pharmacotherapy, adjunctive non-pharmacological treatments, and clinical outcomes. Each chapter of the book is a 'stand-alone' chapter and is written in a clear, accessible style. Written by an author with many years teaching and research experience, this textbook will prove invaluable for students of pharmacology, pharmacy and the medical sciences needing a truly integrated introduction to this exciting field"--Provided by publisher
|
| Subject
|
:
|
Neuropsychopharmacology.
|
| Subject
|
:
|
Therapeutics.
|
| Subject
|
:
|
Central Nervous System Agents-- Therapeutic use
|
| Subject
|
:
|
Central nervous system-- Diseases-- Chemotherapy.
|
| Subject
|
:
|
Central nervous system-- Effect of drugs on.
|
| Subject
|
:
|
Mental Disorders-- drug therapy
|
| Subject
|
:
|
Neuropharmacology-- Methods.
|
| Dewey Classification
|
:
|
615.7/8
|
| LC Classification
|
:
|
RM315
|
| NLM classification
|
:
|
QV 76.5
|
| Added Entry
|
:
|
Ohio Library and Information Network.
|
| |